MYLAN-LOVASTATIN TABLET

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

LOVASTATIN

Dostupné z:

MYLAN PHARMACEUTICALS ULC

ATC kód:

C10AA02

INN (Medzinárodný Name):

LOVASTATIN

Dávkovanie:

20MG

Forma lieku:

TABLET

Zloženie:

LOVASTATIN 20MG

Spôsob podávania:

ORAL

Počet v balení:

100/500

Typ predpisu:

Prescription

Terapeutické oblasti:

HMG-COA REDUCTASE INHIBITORS

Prehľad produktov:

Active ingredient group (AIG) number: 0120669002; AHFS:

Stav Autorizácia:

CANCELLED POST MARKET

Dátum Autorizácia:

2017-08-02

Súhrn charakteristických

_ _
_Product Monograph –Mylan_-_Lovastatin Page 1 of 45_
PRODUCT MONOGRAPH
PR
MYLAN-LOVASTATIN
Lovastatin Tablets, USP
20 mg and 40 mg
LIPID METABOLISM REGULATOR
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Submission Control No.: 172776
Date of Revision: March 26, 2014
_ _
_Product Monograph –Mylan_-_Lovastatin Page 2 of 45 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
13
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
.........................................................................
22
CLINICAL TRIALS
.........................................................................................................
23
DETAILED PHARMACOLOGY
....